Skip to content

Study · Randomized controlled trial · n = 175 · 2019

4 results

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M and 13 more

Show all authors

Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH

Gastroenterology22 Apr 2019Cited by 53 (Europe PMC)

PMID31022403 (opens in a new tab)DOI10.1053/j.gastro.2019.04.018 (opens in a new tab)PepBankPUB-31022403
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In ADPKD with polycystic liver disease, lanreotide reduced hTLV growth by 5.91% versus control (95% CI -9.18 to -2.63, P < .001).

    In plain wordsIn patients with ADPKD and polycystic liver disease, lanreotide reduced liver volume growth by 5.91% versus standard care.

    Peptide
    Lanreotide
    Outcome
    DecreasehTLV growth versus control
    Study

    n = 175

    Comparator
    Standard care
    Analysis
    Primary
    Outcome group
    Liver Volume · Liver
    Studied dose
    120 mg every 4 weeks · subcutaneous · 120 weeksAs given in this study (human).

    Measurements

    Difference in hTLV growth, lanreotide versus control
    −5.91%
    120 weeks
    95% CI of difference in hTLV growth
    −9.18 to −2.63%
    120 weeks
    P value for hTLV growth difference
    < 0.001
    120 weeks

    Source sentences

    Summary
    Compared with the control group, lanreotide reduced the growth of hTLV by 5.91% (95% CI, -9.18 to -2.63; P < .001).
    3 context sentences
    Summary · context
    We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.
    Summary · context
    For this analysis, we studied the 175 patients with polycystic liver disease with hepatic cysts identified by magnetic resonance imaging and liver volume ≥2000 mL.
    Summary · context
    Of these, 93 patients were assigned to a group that received lanreotide (120 mg subcutaneously every 4 weeks) and 82 to a group that received standard care (blood pressure control, a sodium-restricted diet, and antihypertensive agents).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In ADPKD with polycystic liver disease, lanreotide reduced hTLKV growth by 7.18% versus control (95% CI -10.25 to -4.12, P < .001).

    In plain wordsIn patients with ADPKD, lanreotide reduced combined liver and kidney volume growth by 7.18% versus standard care.

    Peptide
    Lanreotide
    Outcome
    DecreaseCombined hTLKV growth
    Study

    n = 175

    Comparator
    Standard care
    Analysis
    Secondary
    Outcome group
    Organ Volume · Liver
    Studied dose
    120 mg every 4 weeks · subcutaneous · 120 weeksAs given in this study (human).

    Measurements

    Difference in hTLKV growth, lanreotide versus control
    −7.18%
    120 weeks
    95% CI of difference in hTLKV growth
    −10.25 to −4.12%
    120 weeks
    P value for hTLKV growth difference
    < 0.001
    120 weeks

    Source sentences

    Summary
    Lanreotide reduced growth of hTLKV by 7.18% compared with the control group (95% CI, -10.25 to -4.12; P < .001).
    3 context sentences
    Summary · context
    We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.
    Summary · context
    For this analysis, we studied the 175 patients with polycystic liver disease with hepatic cysts identified by magnetic resonance imaging and liver volume ≥2000 mL.
    Summary · context
    Of these, 93 patients were assigned to a group that received lanreotide (120 mg subcutaneously every 4 weeks) and 82 to a group that received standard care (blood pressure control, a sodium-restricted diet, and antihypertensive agents).
  3. 03HumanNon-randomized trialEfficacy outcome

    In ADPKD with polycystic liver disease, hTLV decreased by 1.99% from baseline at 120 weeks with lanreotide (95% CI -4.21 to 0.24); in the control group it increased by 3.92% (95% CI 1.56 to 6.28).

    In plain wordsIn ADPKD with polycystic liver disease, liver volume fell 1.99% from baseline with lanreotide and rose 3.92% in controls at 120 weeks.

    Peptide
    Lanreotide
    Outcome
    DecreasehTLV change
    Study

    n = 93

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Liver Volume · Liver
    Studied dose
    120 mg every 4 weeks · subcutaneous · 120 weeksAs given in this study (human).

    Measurements

    hTLV percent change from baseline
    −1.99%
    lanreotide group, 95% CI -4.21 to 0.24
    hTLV percent change from baseline
    3.92%
    control group, 95% CI 1.56 to 6.28

    Source sentences

    Summary
    At 120 weeks, hTLV decreased by 1.99% in the lanreotide group (95% confidence interval [CI], -4.21 to 0.24) and increased by 3.92% in the control group (95% CI, 1.56-6.28).
    3 context sentences
    Summary · context
    We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.
    Summary · context
    For this analysis, we studied the 175 patients with polycystic liver disease with hepatic cysts identified by magnetic resonance imaging and liver volume ≥2000 mL.
    Summary · context
    Of these, 93 patients were assigned to a group that received lanreotide (120 mg subcutaneously every 4 weeks) and 82 to a group that received standard care (blood pressure control, a sodium-restricted diet, and antihypertensive agents).
  4. 04HumanNon-randomized trialEfficacy outcome

    In ADPKD with polycystic liver disease, hTLV growth remained 3.87% lower versus baseline four months after the last lanreotide injection (95% CI -7.55 to -0.18, P = .04).

    In plain wordsIn patients with ADPKD, liver volume growth remained reduced versus baseline four months after the last lanreotide injection.

    Peptide
    Lanreotide
    Outcome
    DecreasehTLV growth after withdrawal
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Liver Volume · Liver
    Studied dose
    120 mg every 4 weeks · subcutaneous · 120 weeksAs given in this study (human).

    Measurements

    hTLV growth versus baseline, 4 months after last injection
    −3.87%
    lanreotide group, 95% CI -7.55 to -0.18
    P value for hTLV growth versus baseline
    0.04
    4 months after last injection

    Source sentences

    Summary
    Growth of hTLV was still reduced by 3.87% at 4 months after the last injection of lanreotide compared with baseline (95% CI, -7.55 to -0.18; P = .04).
    3 context sentences
    Summary · context
    We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.
    Summary · context
    For this analysis, we studied the 175 patients with polycystic liver disease with hepatic cysts identified by magnetic resonance imaging and liver volume ≥2000 mL.
    Summary · context
    Of these, 93 patients were assigned to a group that received lanreotide (120 mg subcutaneously every 4 weeks) and 82 to a group that received standard care (blood pressure control, a sodium-restricted diet, and antihypertensive agents).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT01616927

Study of Lanreotide to Treat Polycystic Kidney Disease

University Medical Center Groningenn = 300Jun 2012 to est. Dec 2017

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Trial pageClinicalTrials.govUpdated 23 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.